Abstract
Objective To analyze differentially expressed proteins in bile of extrahepatic cholangiocarcinoma (EHCC)by proteomics technology, and to detect the potential tumor markers for diagnosis of bile duct malignancy. Methods Bile samples from 16 patients with EHCC and 16 patients with sphincter of oddi dysfunction (control) were collected for proteomic analysis by isobaric tags for relative and absolute quantitation (iTRAQ). The differentially expressed proteins were identified by mass spectrometry and retrieved by protein database. Results Protein maps of both EHCC group and control group were established successfully by iTRAQ. Analysis software identified an average of 275 proteins in EHCC group and 218 proteins in control group. Statistical filter screened 12 proteins of more than double difference, 4 of which were of diagnostic value, identified by mass spectrometry, which were MUC3a, Annexin A3, REG3A and Tumor-associated trypsin inhibitor (TATI). Functional analysis revealed that these proteins were associated with cancer cellular oncogenesis, proliferation, differentiation and metastasis. Conclusion Proteomic analysis by iTRAQ can identify the protein variance in bile of patients with EHCC, and identify four new potential biomarkers correlated with biological behavior of cholangiocarcinoma. Key words: Cholangiocarcinoma; Bile ducts, extrahepatic; Proteomics; Bile; Tumor markers
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
